Improving viral vector safety for gene therapies
Drug Discovery World
AUGUST 21, 2024
Dr Andrea O’Hara, Senior Product Manager at Azenta Life Sciences asks why integration site analysis (ISA) is critical for the safety and efficacy of viral vectors for gene therapy. Integrating vectors such as lentivirus stably insert their payload into the host cell genome, which is advantageous for long-term treatment.
Let's personalize your content